Daniel E. Geffken
Interim Chief Financial OfficerMr. Daniel E. Geffken, M.B.A, also known as Dan, is Senior Financial Advisor of BYOMass, Inc. Mr. Geffken is Chief Financial Officer of Aquinnah Pharmaceuticals, Inc. He was Interim CFO of Opthea Limited from September 9, 2024 to October 28, 2024. He is Interim Chief Financial Officer of Clear Creek Bio, Inc. He is a Co-founder since June 2011 and Managing Director at Danforth Advisors, LLC, which is a part of Danforth Heath, Inc. He is a Chief Financial Officer of Opy Acquisition Corp. I since July 2021 and serves as its Secretary. He serves as an Interim Chief Financial Officer at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He served as chief financial officer of Locust Walk Acquisition Corporation since October 2020. He has been the Chief Financial Officer of Phoenix Biotech Acquisition Corp. since June 2021. He served as an Interim Chief Financial Officer at Vigeo Therapeutics, Inc. He served as an Interim Chief Financial Officer at CalciMedica, Inc. since October 2020 until November 2024. Mr. Geffken serves as Chief Financial Officer at Locust Walk Acquisition Corp., since October 2020. He served as an Interim Chief Financial Officer of Atea Pharmaceuticals, Inc until October 01, 2020. He was Chief Financial Officer of Zikani Therapeutics, Inc. Mr. Geffken served as Interim Chief Financial Officer and Director of Elicio Therapeutics Inc. since 2013 and 2017 respectively. He has been the Chief Financial Officer of ProMIS Neurosciences Inc. since March 22, 2017. Mr. Geffken is the Founder of Danforth Advisors LLC and has been its Managing Partner since October 2011. He served as an Interim Chief Financial Officer at Stealth BioTherapeutics Incorporated. He serves as the Chief Financial Officer of Nemucore Medical Innovations, Inc. He was Independent Director of Windtree Therapeutics, Inc., since April 24, 2019 until August 13, 2024. Mr. Geffken served as an Interim Chief Financial Officer of Apellis Pharmaceuticals, Inc. since August 2015 until October 2017. He has served as CFO and executive-level advisor to numerous companies and is Chief Financial Officer of companies including Matrivax Research & Development Corp., Vaxxinity, Prilenia Therapeutics Development Corp., Apic Bio Inc., Windgap Medical, Inc., Artax BioPharma Inc., Palvella Therapeutics, Inc., Apnimed, Inc., Dermbiont, Inc., AnTolRx, Inc. and Privo Technologies Inc. He was also associated with companies like Cabaletta Bio, Cidara Therapeutics, Editas Medicine, Homology Medicines, Promedior and Stealth BioTherapeutics. He served as an Interim Chief Financial Officer of Marina Biotech, Inc. from May 13, 2014 to October 31, 2016. He served as Principal Financial Officer and Senior Financial Consultant at Gelesis, Inc. He served as an Interim Chief Financial Officer of Novira Therapeutics, Inc. He served as the Chief Operating Officer of Seaside Therapeutics, LLC from October 14, 2009 to 2011 and served as its Chief Financial Officer. He served as the Chief Financial Officer of seven companies, ranging from venture-backed start-ups to publicly held corporations. He served as the Chief Financial Officer of Codon Devices, Inc. since March 21, 2007 and served as its Senior Vice President. He joined Codon Devices in March 2007. He served as the Chief Financial Officer and Executive Vice President of Konarka Technologies, Inc. from August 2006 to March 2007 and served as its Vice President. He served as the Chief Financial Officer and Senior Vice President of Business Development of OmniSonics Medical Technologies, Inc. from December 2003 to August 2006. He joined Omnisonics in December of 2003. He served as the Chief Financial Officer and Vice President of CytoTherapeutics, Inc. He served as the Chief Financial Officer and Treasurer of Shire Human Genetic Therapies, Inc. (also known as Transkaryotic Therapies Inc.) from February 1997 to April 18, 2003 and its Senior Vice President of Finance from December 2000 to April 18, 2003. He served as Vice President of Finance of Transkaryotic Therapies Inc. from February 1997 to December 2000. He held a variety of senior financial roles at Anderson Group (now Moscow CableCom Corp.) and Medchem Products (now C. R. Bard Inc.). He served as a Principal in a private equity firm and was a Certified Public Accountant (CPA) at KPMG. He served as Director of Arcturus Therapeutics Ltd. from November 2017 to May 27, 2018. He served as a Director at Alcobra Pharmaceuticals Inc. from May 2013 to November 2017. As a founder and managing director at Danforth Advisors, he has served as chief financial officer and strategic consultant to life science and biotechnology companies, ranging from start-ups to publicly traded companies, including Apellis Pharmaceuticals, Atea Pharmaceuticals, Cabaletta, Cidara Therapeutics, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. He served as Director of Cyberkinetics Neurotechnology Systems Inc. since January 2005. He has extensive experience in financial strategy and operations. Mr. Geffken received his Bachelor of Science Degree in Economics from The Wharton School at the University of Pennsylvania in 1979 and his MBA from The Harvard Business School in 1987.
Positions
- Company NameEloxx Pharmaceuticals, Inc.Stock CodeELOXPositionInterim Chief Financial OfficerColleagues
- SASumit AggarwalPresident, CEO & Director
- AEAlan Edmund WaltsIndependent Chairman
- JWJohn WoolfordVP & Head of Corporate Development
- RCRoger ClarkVP & Head of Discovery Sciences
- TSTeji SinghVP & Head of Clinical Development
- SDSteven D. RubinIndependent Director
- DBDavid BedwellMember of Scientific Advisory Board
- RGRachel GreenMember of Scientific Advisory Board
